Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBruno Paiva, Jesús F. San Miguel, Raimundo García‐Boyero et al.|Blood|2008Cited by 479
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myelomaBruno Paiva, Jesús F. San Miguel, Norma C. Gutiérrez et al.|Blood|2011Cited by 304
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple MyelomaBruno Paiva, Noemí Puig, María‐Teresa Cedena et al.|Journal of Clinical Oncology|2019Cited by 279
Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 casesRamón García‐Sánz, Jesús F. San Miguel, Silvia Montoto et al.|British Journal of Haematology|2001Cited by 267
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myelomaLaura Rosiñol, Joan Bladé, Albert Oriol et al.|Blood|2019Cited by 218